AXL and acute myeloid leukemia: ASP2215 has an IC50 of 0.7 nM against AXL [93] and 0.29 nM against FLT3 [102] in enzymatic assays, potently inhibits phosphorylation of FLT3 in a FLT3-ITD+ AML cell line, and prolongs survival in orthotopic xenograft models of FLT3-ITD+ AML.